ArticleGut microbes reports2026
Longitudinal multi-omic dynamics in hospitalized COVID-19 patients based on disease severity.
Article in Gut microbes reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite a decline in global COVID-19 cases, severe disease requiring hospitalization remains a significant health burden. Microbial dysbiosis and microbial translocation have been implicated in COVID-19 severity through their contributions to systemic inflammation, yet the temporal dynamics of the microbiome and related metabolites across disease severity are not well defined. To address this, we conducted a longitudinal study of 22 hospitalized COVID-19 patients in Milan, Italy, classified as moderate, severe, or critical by the WHO criteria. Rectal and nasal microbiomes, plasma cytokines, bile acids, fatty acids, and gut barrier damage markers were measured at up to three timepoints over an average of 9 d. Critically ill patients exhibited sustained elevations in pro-inflammatory cytokines (IL-6, IL-8, and TNFα), increased gut barrier damage markers (LBP, zonulin, and sCD14), early depletion of beneficial commensals (including Faecalibacterium prausnitzii), and expansion of opportunistic pathogens such as Hungatella hathewayi and Erysipelatoclostridium ramosum. These microbial shifts were accompanied by the progressive loss of secondary and conjugated bile acids and increased levels of branched- and medium-chain fatty acids. Correlation analyses linked commensal taxa to reduced gut barrier damage and opportunistic pathogens to IL-6. Together, these findings define distinct trajectories associated with COVID-19 severity and highlight the importance of early interventions targeting microbial dysbiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.